E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Spontaneous, serious, nosebleeds (nosebleeds that occur in the absence of trauma/injury and that fail to stop after first aid treatment). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10015090 |
E.1.2 | Term | Epistaxis |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main research question is: Does treatment with intranasal TXA, in addition to standard first aid measures and topical vasoconstrictor treatment, reduce the need for nasal packing in adult patients presenting to the Emergency Department with spontaneous nosebleeds?
In lay language, the research question is: For patients attending the Emergency Department (Accident and Emergency) with a serious nosebleed, can tranexamic acid applied inside the bleeding nostril reduce the need for nasal packing (a large dressing filling the nostril)? |
|
E.2.2 | Secondary objectives of the trial |
• any further treatment for nosebleed during the ED attendance • hospital admission and subsequent length of stay, measured in days • blood transfusion during hospital attendance • number of repeat nosebleeds within one week of initial ED attendance • any thrombotic (blood clot) event requiring any hospital re-attendance within one week of initial ED attendance • any further hospital treatments required for nosebleeds during the one week follow-up period, including details of the type of hospital episode • adverse events occurring up to one week after trial treatment
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Potential participants must satisfy the following criteria to be enrolled in the study: • Aged 18 or over • Presenting to the ED with spontaneous, atraumatic epistaxis, unresolved with simple first aid and standard initial therapy.
|
|
E.4 | Principal exclusion criteria |
Potential participants meeting any of the following criteria will be excluded from study participation: • Clinical evidence of shock, as determined by the treating clinician, or requirement for resuscitation (including but not limited to systolic BP< 90 mmHg). • Known allergy to TXA • Lacking capacity • Unwilling to give consent • No telephone or unwilling to be contacted by telephone • Known paranasal, nasopharyngeal or nasal cavity malignancy • Pregnancy • Sent to ED for specialist ENT treatment • Already undergone pre-hospital nasal packing • Prior participation in the study (i.e. received allocated treatment) • Prisoners • Epistaxis caused by trauma (excluding simple nose picking) • Known haemophilia
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Use of anterior nasal packing (of any type) for treatment of epistaxis at any time during the ED attendance. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Discharge from ED to home, or admission to hospital ward. |
|
E.5.2 | Secondary end point(s) |
• any further treatment for epistaxis during the index ED attendance • hospital admission and subsequent length of stay, measured in days • blood transfusion during hospital attendance • incidence of recurrent epistaxis following trial intervention and within 7 days of the index ED attendance • any thrombotic event requiring any hospital re-attendance within 7 days of the index ED attendance • any further hospital treatments required for epistaxis within 7 days of the index ED attendance, including details of the type of hospital episode • adverse events occurring within 7 days of the index ED attendance
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Discharge from the ED either to home or admitted for inpatient stay to a ward.
The follow-up phone call will be made between 7-14 days after the index attendance to the ED. Efficacy and safety data will be collected for the 7 day period post index attendance at the ED. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Completion of last participant's one week telephone follow-up. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |